Study on PK of Hydronidone in Patients and Special Population

Summary

1. Evaluate the pharmacokinetic (PK) characteristics of Hydronidone capsule in target patients (patients with chronic viral hepatitis b with liver fibrosis) and special population (patients with mild liver dysfunction). 2. To evaluate the effect of oral Hydronidone capsule on QT/QTc in patients with chronic viral hepatitis b accompanied by hepatic fibrosis and mild hepatic dysfunction.

Timeline

Start

2019-09-03

Primary completion

2020-10-09

Completion

2021-01-30

Drugs

Indications